Allianz SE

  • WKN: 840400
  • ISIN: DE0008404005
  • Land: Deutschland

Nachricht vom 04.10.2021 | 16:52

Allianz SE: Release of a capital market information

Allianz SE / Announcement pursuant to Art. 5 (1) lit. b) of Regulation (EU) No 596/2014 and Art. 2 (3) of Delegated Regulation (EU) No2016/1052 / Acquisition of own shares
04.10.2021 / 16:52
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

 

Munich, 4.10.2021

In the period from September 27, 2021 to, and including, October 1, 2021 Allianz SE has purchased a number of 487,578 shares within the framework of its ongoing share buy-back program which has been published by the announcement of August 17, 2021 pursuant to Art. 5 (1) lit. a) Regulation(EU) No 596/2014 and Art. 2 (1) Delegated Regulation (EU) No 2016/1052.

Shares were purchased as follows:

Date               Number of shares           Average price (EUR)

27.09.2021                   93,600                     195.6592
28.09.2021                  112,121                    195.8594
29.09.2021                    92,300                    195.4601
30.09.2021                    96,257                    195.1248
01.10.2021                    93,300                    194.6544




The total number of shares purchased in the context of the share buy-back program since August 18, 2021 through, and including, October 1, 2021 amounts to 2,947,162.

The purchase of shares is carried out exclusively on the electronic trading platform of the Frankfurt Stock Exchange (Xetra) by a credit institution that has been commissioned by Allianz SE.

Detailed transaction information pursuant to Art. 2 (3) Delegated Regulation(EU) No 2016/1052 can be found on the website of Allianz SE (www.allianz.com).



04.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021